Den europeiske union - norsk - EMA (European Medicines Agency)

sandoz gmbh - trastuzumab - breast neoplasms; stomach neoplasms - antineoplastiske midler - treatment of metastatic and early breast cancer and metastatic gastric cancer (mgc).

Norge - norsk - Statens legemiddelverk

dr. falk pharma gmbh - mesalazin - rektalskum - 1 g/ dose

Norge - norsk - Statens legemiddelverk

karo pharma as - tramadolhydroklorid / paracetamol - tablett - 37.5 mg / 325 mg

Norge - norsk - Statens legemiddelverk

curium netherlands b.v. - natriumjodid (131i) - kapsel, hard

Norge - norsk - Statens legemiddelverk

ge healthcare buchler gmbh & co. kg - natriumjodid (131i) - kapsel, hard

Den europeiske union - norsk - EMA (European Medicines Agency)

eli lilly nederland b.v. - abemaciclib - bryst neoplasms - antineoplastiske midler - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

Norge - norsk - Statens legemiddelverk

animedica gmbh - menbuton - injeksjonsvæske, oppløsning - 100 mg/ ml

Norge - norsk - Statens legemiddelverk

2care4 aps - prasteron - vagitorie - 6.5 mg

Den europeiske union - norsk - EMA (European Medicines Agency)

astrazeneca ab - fulvestrant - bryst neoplasms - endokrin terapi, anti-østrogener - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. i pre - eller perimenopausal women, kombinert behandling med palbociclib bør kombineres med en luteiniserende hormon-frigjørende hormon (lhrh) agonist.

Norge - norsk - Statens legemiddelverk

cis bio international - natriumjodid (131 i) - kapsel, hard - 50 mbq